Cases & Deals

Baxter Ventures invests in True North Therapeutics

Clients Baxter International Inc.

Jones Day represented Baxter Ventures in connection with its purchase of Series A Preferred Stock in a private placement by True North Therapeutics, Inc., a biotechnology company that develops treatments for rare diseases. Co-investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, and Biogen Idec New Ventures.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.